-
The extra opportunities offer the most benefit
“The Bridge Program provides lots of opportunities that help you stand out in your career. It's these opportunities that provide added benefit and offer something special.” -
Embracing industry partnerships to boost disease-fighting research
"The connections I made and what I learnt are already impacting on my commercialisation pathway.” -
Bridging the pathway to improved human health
“Through the Bridge program, you get to meet really seasoned, intelligent industry folk that you might not normally get to meet. That helped shape my interest in the field of drug development." -
Connecting discovery with commercialisation
"By combining my drug discovery experience with the skills and knowledge I gained through the Bridge Program, I feel I have a greater capacity to direct the development of new therapeutics." -
Concise, comprehensive and well informed
"I’ve sought out many resources on the topic and nothing has compared to the Bridge Program." -
Realising potential for the greater good
“I was not aware of the commercial potential of my research. But through the program I realised that it might be possible for my research to have a more translational impact.” -
Practical insights for success
"It was such a practical program, through the contact it offered with industry partners, intensive workshops and learning how to pitch ideas to a top pharmaceutical company."
Bridge Program alumnus Prof Flavia Huygens.
Executive Director, Founder & Chief Scientific Officer, Microbio.
Our 2024 program
Who are our participants?
Up to 100 participants are selected annually from across Australia. The program is suited to mid-career professionals looking to expand their commercialisation knowledge and networks, including:
- researchers
- scientists
- entrepreneurs
- legal practitioners (including IP and patents)
- clinicians
- venture capitalists
- business development personnel
- staff from regulatory and government agencies
A pharmaceutical or biotech background and a demonstrated interest in commercialisation is essential.
Applications 2024 are now closed.
Thank you to everyone who applied.
We will email you to let you know the outcome of your application in early Quarter 2.
More information